Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

117m Sn DTPA

Drug Profile

117m Sn DTPA

Alternative Names: Pentetate 117m Sn; Stanamet; Tin-117m DTPA

Latest Information Update: 05 Jun 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Developer Bayer Schering Pharma; Nonindustrial source
  • Class Analgesics; Radiopharmaceuticals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bone cancer; Cancer pain

Most Recent Events

  • 17 Jun 2004 Discontinued - Phase-II for Cancer pain in USA (unspecified route)
  • 16 Nov 1999 Diatide has been acquired by Schering AG
  • 01 Jul 1999 The US Department of Energy will give Brookhaven National Laboratory US$750,000 over 3 years to develop Stanamet
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top